In silico design of clinical trials: A method coming of age

  title={In silico design of clinical trials: A method coming of age},
  author={Gilles Clermont and John Bartels and Rukmini Kumar and Gregory M Constantine and Yoram Vodovotz and Carson C. Chow},
  journal={Critical Care Medicine},
Objective:To determine the feasibility and potential usefulness of mathematical models in evaluating immunomodulatory strategies in clinical trials of severe sepsis. Design:Mathematical modeling of immunomodulation in simulated patients. Setting:Computer laboratory. Measurements and Main Results:We introduce and evaluate the concept of conducting a randomized clinical trial in silico based on simulated patients generated from a mechanistic mathematical model of bacterial infection, the acute… 
In Silico Trials and Personalized Therapy for Sepsis and Trauma
It is suggested that mechanistic computational modeling can provide a rational strategy for enhancing and integrating the currently fragmented process by which therapeutic targets and candidates are selected, by which clinical trials of existing and emerging therapeutics could be tailor to a given disease, and by which diagnosis and therapy could be tailored to the individual patient.
Arguing for Adaptive Clinical Trials in Sepsis
Challenges in the evaluation of treatments for sepsis are discussed, and potential benefits and weaknesses of recent advances in adaptive trial methodologies are explored to address these challenges.
Translational Systems Approaches to the Biology of Inflammation and Healing
An iterative and ongoing program of literature analysis, generation of prospective data, data analysis, and computational modeling in various experimental and clinical inflammatory disease settings has suggested how to modulate acute inflammation in a rational, individually optimized fashion.
Translational systems biology of inflammation: potential applications to personalized medicine.
It is suggested that the work aimed at creating a rational, engineering-oriented and evidence-based synthesis of inflammation geared towards rapid clinical application is on the cusp of fulfilling the promise of in silico modeling for personalized medicine for inflammatory disease.
Mathematical models of the acute inflammatory response
Simulations using various methods can shed insight into the pathophysiology of the acute inflammatory response and may lead to better design of clinical trials in sepsis and trauma.
Translational systems biology of inflammation and healing
  • Y. Vodovotz
  • Biology
    Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
  • 2010
These simulations transcend typical cytokine networks by associating inflammatory processes with tissue/organ damage via tissue damage/dysfunction and suggest that computational simulations are the cornerstone of Translational Systems Biology approaches for inflammatory diseases.
Development of Synthetic Patient Populations and In Silico Clinical Trials
This chapter discusses pioneering work on the use of in silico clinical trials to accelerate the development of new drugs and heterogenous datasets, such as Electronic Health Records (EHRs), to build synthetic populations of patients and personalized, predictive models of response to therapy.
Personalized Mathematical Model Predicting Endotoxin-Induced Inflammatory Responses in Young Men
A personalized mathematical model is created that can accurately determine individual differences between subjects, as well as identify those who showed an abnormal response to pathogenic microbial infection.
Predicting Experimental Sepsis Survival with a Mathematical Model of Acute Inflammation
Simulated trajectories of bacteria, inflammatory responses, and damage were closely clustered during the initial stages of infection, suggesting that uncertainty in initial conditions could lead to difficulty in predicting outcomes of sepsis by using inflammation biomarker levels.
Genomic Variations and Susceptibility to Sepsis
A theoretical framework for incorporation of genetic variations into individualized care planning based on complexity theory is proposed, and future prospects of microarray technology and systems modelling are discussed briefly.


Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned
Analysis of all trial data as well as data from a recent trial in a large population of septic patients show that anti-TNF strategies may confer a small survival benefit, and better characterization of patients and a more multimodal approach by concomitantly targeting other mediators involved in sepsis may be helpful in enlarging the clinical benefit of anti- TNF therapy.
A New Paradigm for the Treatment of Sepsis: Is It Time To Consider Combination Therapy?
This study, the largest clinical trial for sepsis to date, randomly assigned more than 3000 patients to receive one of several doses of a Fab component of a monoclonal antibody against tumor necrosis factor (TNF) or placebo and there was a small improvement in mortality that mirrored the data presented in their meta-analysis.
Cytokine therapeutics for the treatment of sepsis: why has nothing worked?
  • D. Remick
  • Biology, Medicine
    Current pharmaceutical design
  • 2003
The concept of blocking a single elevated cytokine may be too simple to deal with the complex problem of sepsis and there may be intervals when it is appropriate to inhibit multiple cytokines while at other times it may be appropriate to augment the immune response.
Influence of an anti‐tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis
The murine monoclonal anti-TNF antibody was well tolerated despite the development of anti-murine antibodies in 98% of patients and no survival benefit was found for the total study population.
Effects of genomic polymorphisms on the course of sepsis: is there a concept for gene therapy?
  • F. Stüber
  • Biology, Medicine
    Journal of the American Society of Nephrology : JASN
  • 2001
Genomic information may be used to identify groups of patients with a high risk of developing severe sepsis and multiple organ dysfunction, and determining which patients will benefit from antimediator strategies because of their genetic determination to high cytokine release in the inflammatory response will be the subject of future trials.
Clinical Trial Design and Outcomes in Patients with Severe Sepsis
Because drotrecogin alfa (activated) is the only Food and Drug Administration-approved therapy for severe sepsis, the Phase 3 Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial results will be discussed in detail to help define a model for further clinical trials on severe sePSis.
Genetic variation in proinflammatory and anti-inflammatory cytokine production in multiple organ dysfunction syndrome*
A genetic predisposition to high interleukin-10 production or intermediate TNF-&agr; production in vitro may be protective of admission to the intensive care unit, although once admitted, any protection provided by these genotypes seems to be lost.
Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy.
The evidence for a genetic susceptibility to development of sepsis and death from sepsic shock is summarized, the design of clinical genetics studies relevant to the study of complex disorders are discussed, the candidate genes likely to be involved in the pathogenesis of sePSis are considered, and the potential for targeted therapy of septic shock based on genetic variability is discussed.